Cargando…

Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) constitute a drug class primarily developed for the treatment of subjects with type 2 diabetes, although they have also provided significant benefit for subjects with obesity without underlying diabetes. Individuals with psychotic di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Michailidis, Theodoros, Dimosiari, Athina, Fragakis, Nikolaos, Tse, Gary, Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045529/ https://www.ncbi.nlm.nih.gov/pubmed/36979648 http://dx.doi.org/10.3390/biomedicines11030669

Ejemplares similares

Takayasu Arteritis is Associated with Impaired Arterial Stiffness: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed?
por: Dimosiari, Athina, et al.
Publicado: (2022)

The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Effect of COVID-19 on endothelial function evaluated with flow-mediated dilation: another prognostic marker? A meta-analysis of observational studies
por: Dimosiari, Athina, et al.
Publicado: (2022)

Intravenous pulse methylprednisolone for the treatment of severe COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2023)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
por: Dimosiari, Athina, et al.
Publicado: (2023)

Anti-Interleukins for Severe Coronavirus Disease-2019: Hype or Hope?
por: Dimosiari, Athina, et al.
Publicado: (2022)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Rhabdomyolysis Induced by Coadministration of Fusidic Acid and Atorvastatin: A Case Report and Comprehensive Review of the Literature
por: Patoulias, Dimitrios, et al.
Publicado: (2017)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis
por: Khaity, Abdulrhman, et al.
Publicado: (2023)

Comparing Efficacy and Safety in Catheter Ablation Strategies for Paroxysmal Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials
por: Charitakis, Emmanouil, et al.
Publicado: (2022)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis
por: Dimopoulou, Despoina, et al.
Publicado: (2017)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis
por: Zhuo, Chuanjun, et al.
Publicado: (2021)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Laparoscopic parastomal hernia repair: keyhole, Sugarbaker, sandwich, or hybrid technique with 3D mesh? An updated systematic review and meta-analysis
por: Kritharides, Nicos, et al.
Publicado: (2023)

Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
por: Huang, Xiao-Min, et al.
Publicado: (2023)

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
por: Michos, Erin D., et al.
Publicado: (2023)

Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
por: Patoulias, D., et al.
Publicado: (2022)

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications
por: Jensterle, Mojca, et al.
Publicado: (2021)

PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment
por: Babic, I, et al.
Publicado: (2016)

Gut Microbiota Modification via Glucagon-like Peptide-1 with Beneficial Neuroprotective Effects
por: Sayehmiri, Fatemeh, et al.
Publicado: (2022)

Platelet rich plasma effectiveness in bowel anastomoses: A systematic review
por: Geropoulos, Georgios, et al.
Publicado: (2021)

Antipsychotics in the Treatment of Children and Adolescents with Anorexia Nervosa: A Systematic Review
por: Pruccoli, Jacopo, et al.
Publicado: (2022)

Fever and temporal headache in a 70-year-old male with presumed large vessels vasculitis
por: Vettas, Christos, et al.
Publicado: (2019)

Overweight trajectory and cardio metabolic risk factors in young adults
por: Callo Quinte, Gabriela, et al.
Publicado: (2019)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia
por: Sampogna, Gaia, et al.
Publicado: (2023)

Artificial intelligence-based mining of electronic health record data to accelerate the digital transformation of the national cardiovascular ecosystem: design protocol of the CardioMining study
por: Samaras, Athanasios, et al.
Publicado: (2023)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8k48oeeujllief39oi26adgrsl